Boehringer Ingelheim is continuing to explore its newfound enthusiasm for eye health, penning a $1 billion biobucks pact with ...

Family-owned Boehringer Ingelheim, now Germany’s largest drugmaker by revenue, has reported positive growth in the first half ...

Ingelheim: Boehringer Ingelheim and Re-Vana Therapeutics, a US and UK-based developer of ocular therapeutics and ocular drug ...

Re-Vana Therapeutics develops products to improve the delivery of drugs for chronic eye diseases, increasing the quality of ...

Boehringer Ingelheim partners with Re-Vana Therapeutics to innovate long-acting eye disease treatments, enhancing patient care and compliance.

Re-Vana’s drug delivery technology is designed to release treatments over a 6- to 12-month period, with the goal of reducing ...

Boehringer Ingelheim and Re-Vana Therapeutics, a U.S. and UK based developer of ocular therapeutics and drug delivery ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

The German giant is looking to develop new drugs for undisclosed eye diseases using Re-Vana’s extended-release injectable ...

Re-Vana Therapeutics has entered a partnership and licence agreement with Boehringer Ingelheim for the development of eye therapies.

It's shaping up to be a big year for Boehringer Ingelheim—at least if the FDA plays ball. | Boehringer Chief Medical Officer Lykke Hinsch Gylvin, M.D., set out the German drugmaker's plans to launch ...

Queens University spin-out Re-Vana Therapeutics has agreed a $1bn deal with biopharma giant Boehringer Ingelheim.